Delivery Order SPE2DB20D2014-SPE2DB25FC17F
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $2,291.00 and an ultimate completion date of June 17, 2025. The contract carries no set-aside designation, indicating it was awarded through competitive procurement. Performance will be executed from AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency awarded a $5,629.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, which is also the headquarters location of the prime contractor. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a ceiling value of $2,323.73. This contract represents a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and was competitively awarded without set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count) with a contract ceiling value of $9,131.84. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with a ceiling value of $18,546.84 and an ultimate completion date of November 10, 2025. The contract has no set-aside designation, indicating it was competitively awarded. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units. This contract, valued at $1,605.20, is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a contract ceiling value of $4,134.12. This is a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 14, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside delivery order carries a ceiling value of $6,130.99 under a firm fixed-price arrangement, with an ultimate completion date of November 17, 2025. The order will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC17FDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 10, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a contract ceiling value of $4,745.90. This is a firm fixed price delivery order with no set-aside designation, awarded through open competition to the prime contractor. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract is scheduled for ultimate completion on June 11, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at approximately $1 billion through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. The ondansetron order reflects the company's role in providing critical pharmaceutical commodities across multiple therapeutic domains to support Defense Health Agency operations and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 6/10/25 |